Assembly Biosciences (NASDAQ: ASMB) and Repligen Corporation (NASDAQ:RGEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.
This table compares Assembly Biosciences and Repligen Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
72.4% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 97.9% of Repligen Corporation shares are owned by institutional investors. 19.6% of Assembly Biosciences shares are owned by insiders. Comparatively, 1.5% of Repligen Corporation shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Assembly Biosciences has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Repligen Corporation has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Assembly Biosciences and Repligen Corporation, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Assembly Biosciences presently has a consensus target price of $35.00, suggesting a potential upside of 16.05%. Repligen Corporation has a consensus target price of $46.00, suggesting a potential upside of 18.80%. Given Repligen Corporation’s higher probable upside, analysts plainly believe Repligen Corporation is more favorable than Assembly Biosciences.
Valuation & Earnings
This table compares Assembly Biosciences and Repligen Corporation’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Assembly Biosciences||N/A||N/A||-$44.26 million||($2.93)||-10.29|
|Repligen Corporation||$104.54 million||12.62||$11.68 million||$0.51||75.92|
Repligen Corporation has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.
Repligen Corporation beats Assembly Biosciences on 10 of the 12 factors compared between the two stocks.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
What are top analysts saying about Assembly Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Assembly Biosciences Inc. and related companies.